Adverum Biotechnologies Inc

Adverum Biotechnologies — Avalanche Biotechnologies — Merger or Acquisition (February 2016)

34 slides from Adverum Biotechnologies's merger presentation, Feb 22, 2016

  1. Slide 1: The Science Behind Annapurna

    The Science Behind Annapurna R. Crystal Department of Genetic Medicine Weill Cornell Medical College 2-17-16 Exhibit 99.1

  2. Slide 2: Cautionary Statements Regarding Forward-Looking Statements

    Cautionary Statements Regarding Forward-Looking Statements Statements contained in this document regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include, but are n

  3. Slide 3: Additional Information and Where To Find It

    Additional Information and Where To Find It This document not constitute a solicitation of any vote or approval. In connection with the proposed transaction, Avalanche intends to file with the SEC a proxy statement of Avalanche, as well as other relevant documents concerning the proposed transaction

  4. Slide 4: Why Gene Therapy?

    Why Gene Therapy ? Gene Modify gene expression Modify phenotype Advantages Versatile protein delivery system Persistent expression Local delivery

  5. Slide 5: Basic Concept of Gene Therapy

    Basic Concept of Gene Therapy Therapeutic gene Human genome m m m m m m m m m m m m m m m m m m Delivery vehicle (vector) Target organ m m m m m m m m m m m m m m m m m m

  6. Slide 6: Challenges of Gene Therapy

    Challenges of Gene Therapy Challenges Target choice – need, feasibility Targeting to site of disease Level of expression required Robust phenotype, clear demonstration of efficacy using FDA-acceptable parameters Safety – risk/benefit, dose-limiting immune related toxicity, lack of control of express

  7. Slide 7: Annapurna Programs

    Annapurna Programs Alpha 1-antitrypsin deficiency Hereditary angioedema Friedreich’s ataxia cardiac disease Severe allergy

  8. Slide 8: AAVrh.10 Vectors

    AAVrh.10 Vectors ITR y ITR ITR CAG promoter Therapeutic gene (cDNA) Genome Capsid serotype AAVrh.10 AAV2 AAV2 Therapeutic genes Alpha 1-antitrypsin C1-esterase inhibitor Frataxin Anti-IgE

  9. Slide 9: Why Gene Therapy?

    Why Gene Therapy? Alpha 1-antitrypsin deficiency, hereditary angioedema, severe allergy Reduced treatment burden Ideal pharmacokinetics - constant levels For hereditary angioedema and severe allergy, eliminate risk for attacks without need for immediate medical care Friedreich’s ataxia cardiac disea

  10. Slide 10: Alpha 1-Antitrypsin Deficiency

    Alpha 1-Antitrypsin Deficiency Common autosomal recessive disorder characterized by a marked reduction in serum a1AT levels Estimated 90,000 affected individuals in US Emphysema develops at ages 35-45 in cigarette smokers, 55-65 in non-smokers Small % develop liver cirrhosis a1AT normally protects t

  11. Slide 11: Pathogenesis of α1-Antitrypsin Deficiency

    Pathogenesis of α1-Antitrypsin Deficiency α1-antitrypsin Neutrophil elastase Lungs Liver Neutrophils Bone marrow Glu342GAG Lys342AAG Z mutation Liver hepatocyte

  12. Slide 12: Augmentation Therapy with Purified Human a1-Antitrypsin

    Augmentation Therapy with Purified Human a1-Antitrypsin Developed by Gadek and Crystal in 1981 FDA approved in 1988 Administration IV 60 mg/kg (~4 g), once weekly Safe - minimal adverse reactions Cost ~$100,000/yr

  13. Slide 13: Logic Underlying Biochemical Efficacy for the Lung Manifestations

    Lungs Liver Bone marrow Neutrophils Neutrophil elastase α1-antitrypsin A. Pathogenesis D.Epithelial lining fluid anti-neutrophil elastase capacity before and after augmentation therapy Normal ZZ pre-therapy ZZ 6 days post- therapy 1 2 3 4 5 ELF anti-neutrophil elastase capacity (mM) C.Serum α1AT fol

  14. Slide 14: Association of a1-Antitrypsin Serum Levels and Risk for Emphysema

    Association of a1-Antitrypsin Serum Levels and Risk for Emphysema MM MS SS MZ SZ ZZ Threshold 11 mM Null 0 10 20 30 40 50 a1AT serum level (mM) Phenotype At risk for emphysema Background risk

  15. Slide 15: Logic for Intrapleural Gene Transfer to Treat α1-antitrypsin Deficiency

    unidirectional valve parietal extrapleural interstitium parietal lymphatic pleural space stoma microvilli basal lamina parietal pleural visceral pleural capillary pulmonary interstitum alveolus pulmonary lymphatic A. Anatomy of the human pleura AAV vector coding for normal human a1AT B.Intrapleural

  16. Slide 16: Serum Human a1AT Levels Following Intrapleural Administration of 25 AAV Serotypes

    Time post-injection (wk) Serum human a1-antitrypsin levels (% of maximum) 0.1 1 10 100 0 1 2 3 4 Undetectable AAVch.5 AAVhu.11 AAVhu.41 AAVhu.47 AAVrh.34 AAVhu.1 AAVhu.13 AAVrh.16 AAVrh.24 AAVrh.22 AAVrh.21 AAVrh.13 AAVbb.2 AAV2 AAVcy.5 AAV7 AAVrh.2 AAVrh.8 AAVrh.43 AAVrh.20 AAVhu.37 AAV5 AAV9 AAV8

  17. Slide 17: Time Course of Serum Human α1AT Levels After AAVrh.10hα1AT

    0 1 2 4 6 12 1 10 102 103 104 24 Time post-injection (wk) Human a1AT level in serum (mg/ml) Naive AAVrh.10hα1AT 0-24 wk Evaluate AAVrh.10hα1AT 1011 genome copies (gc) Intrapleural Human α1AT level in serum (ELISA) C57BL/6 mice n = 4/group Time Course of Serum Human α1AT Levels Following Intrapleural

  18. Slide 18: Human α1AT Levels in Bronchoalveolar Lavage Fluid Compared to Serum

    12 wk Evaluate Serum and lavage human α1AT (ELISA) C57BL/6 mice n = 4/group Human α1AT Levels in Bronchoalveolar Lavage Fluid Compared to Serum Following Intrapleural Administration of AAVrh.10hα1AT Human a1AT (mg/mg protein) Naive AAVrh.10hα1AT Serum Serum Lavage Lavage 0 10 20 30 40 AAVrh.10hα1AT

  19. Slide 19: Intrapleural Administration of AAVrh.10hα1AT to African Green Monkeys

    Ultrasonography-guided Intrapleural Administration of AAVrh.10hα1AT to African Green Monkeys Single intrapleural injection of 1012 or 1013 genome copies of AAVrh.10ha1AT to African Green Monkeys (n=36) Quantify human α1AT mRNA in chest wall up to 1 yr All safety / toxicology parameters normal at all

  20. Slide 20: Hereditary Angioedema

    Hereditary Angioedema Autosomal dominant disorder associated with episodic attacks of swelling of face, extremities, genitals, GI tract and upper airways Airway edema can be life threatening Triggered by trauma, surgery, dental work, menstruation, medications, viral illness, stress Affects 1 in 10,0

  21. Slide 21: Hereditary Angioedema (2)

    Hereditary Angioedema (2) Caused by mutations of the SERPING1 gene, coding for C1 esterase inhibitor (C1EI) that regulates the complement system C1EI - single chain, 510 residue, 105 kDa, glycosylated serine anti-protease expressed 10 by hepatocytes SERPING1 mutations result in reduced serum levels

  22. Slide 22: Gene Therapy for Hereditary Angioedema

    Gene Therapy for Hereditary Angioedema Proof-of-concept studies cannot be discussed at this time due to patent filings in progress

  23. Slide 23: Friedreich Ataxia

    Friedreich Ataxia Approximately 5,000 patients in the US, 5,000-10,000 in Europe Autosomal recessive, results from variants in the frataxin (FXN) gene, a nuclear gene coding for a mitochondrial protein associated with iron sulfur clusters Impairs dorsal root ganglia, spinal cord and cerebellum resul

  24. Slide 24: MCK Mouse Model Recapitulating the Cardiomyopathy of Friedreich Ataxia

    MCK Mouse Model Recapitulating the Cardiomyopathy of Friedrich Ataxia Absence of the frataxin protein in myocardium and skeletal muscle MCK 4 5 7 11 0 Death 8 Progressive left ventricle (LV) systolic dysfunction Cell death and fibrosis Progressive LV hypertrophy and dilation Progressive cardiomyopat

  25. Slide 25: MCK Mice in Heart Failure Treated with AAVrh.10.hFXN

    3 MCK Evaluation of survival and multiple cardiac phenotypes 5 7 Intravenous AAVrh10.hFXN 5.4x1013 vg/kg) 22 35 60 Time (wk) MCK Mice in Heart Failure Treated with AAVrh.10.hFXN Advanced heart failure

  26. Slide 26: AAVrh10hFXN Treatment of MCK Mice with Heart Failure at 7 wk

    Untreated AAVrh10hFXN-treated Normal A. Correction of hypertrophy B. Correction of cardiac function C. Survival Some treated mice die from late myopathy (MCK mice, not patients, have myopathy) AAVrh10hFXN Treatment of MCK Mice with Heart Failure at 7 wk - Rapid Normalization 22 18 14 10 20 16 12 8 0

  27. Slide 27: Identifying a Robust Cardiac Phenotype for Cardiac Friedreich's Ataxia

    Identifying a Robust Cardiac Phenotype for Cardiac Freidreich’s Ataxia Gene Therapy Studies to identify cardiac parameters Department of Genetic Medicine, Weill Cornell Hôpital Universitaire Pitié-Salpêtrière, Paris Parameters Genetic Neurologic Cardiac Serology Cardiac echo Cardiac mri Exercise CDG

  28. Slide 28: Severe Allergy – Example Peanut Allergy

    Severe Allergy – Example Peanut Allergy Common food allergy, manifests with itchiness, urticaria, swelling, eczema, asthma, abdominal pain, hypotension and anaphylaxis Can be fatal 0.4–0.6% US population, 4,000 diagnosed/yr (11/day); most common cause of anaphylaxis in children presenting to the eme

  29. Slide 29: Anti-IgE Therapy of Peanut Allergy

    Anti-IgE Therapy of Peanut Allergy Omalizumab (Xolair) is a humanized IgG1 anti-IgE monoclonal that binds to Fc portion of circulating IgE, preventing the IgE from binding to, and triggering, mast cells Mast cell mediators Y Y Y Y Peanut-specific IgE Y Y Mast cell Exposure to peanuts + Peanut antige

  30. Slide 30: Characterization of Humanized NOD-scid IL2 Rgammanull Mice

    Characterization of NOD-scid IL2 Rgammanull Immunodeficient Mice Humanized with Immune Cells from Peanut Allergic and Control Donors PBMC from donor with no peanut allergy D. Post-peanut challenge PBMC from donor with peanut allergy PBMC from donor with no peanut allergy IgE response pre-/post-peanu

  31. Slide 31: Expression of AAVrh.10Anti-hIgE in NOD-scid IL2 Rgammanull Mice

    Expression of AAVrh.10Anti-hIgE in NOD-scid IL2 Rgammanull Mice 2-44 wk Evaluate AAVrh.10anti-hIgE AAVrh.10IgGcontrol 1011 gc, intravenous Serum anti-hIgE antibody titer (every 2 wk) Nodscid IL2rγnull (n=4F/group) (6-8 wk) Time post-injection (wk) Serum anti-hIgE (μg/ml) AAVrh.10anti-hIgE AAVrh.10Ig

  32. Slide 32: Treatment of Peanut Antigen-Induced Systemic Anaphylaxis with AAVrh.10anti-hIgE

    Treatment of Peanut Antigen-Induced Systemic Anaphylaxis by Treatment with AAVrh.10anti-hIgE; Clinical and Molecular Phenotype A. Post-peanut (PN) challenge clinical phenotype Donor with PN allergy + omalizumab Donor with PN allergy + AAVrh.10anti-hIgE wk 10 (5 wk after therapy) wk 10 (5 wk after th

  33. Slide 33: Mouse Survival Following Treatment with AAVrh.10anti-hIgE, Xolair or Control

    Mouse Survival Following Treatment with AAVrh.10anti-hIgE, Xolair Alone or Control Vector p<0.03 p<0.01 p<0.01 AAVrh.10IgGcontrol Omalizumab AAVrh.10anti-hIgE 100 60 40 20 0 80 0 30 20 10 40 Survival (%) Days after therapy

  34. Slide 34: Gene Therapy

    Gene Therapy Gene Modify gene expression Modify phenotype

Avalanche Biotechnologies — Merger or Acquisition (February 2016) on 6ix